Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world safety and efficacy of QL1706-based treatment in solid tumors
ChiCTR2500106339Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Public Health Clinical Center
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL1706 in Nonhematologic neoplasms, sponsored by Shandong Provincial Public Health Clinical Center. Primary endpoint: Safety (incidence and severity of adverse events). Planned start Jul 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2500106339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106339.